Please Wait.....
Report
Spain Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-06-01 I 71 Pages I Allied Market Research
The Spain point-of-care glucose testing market is experiencing significant growth during the forecast period. This is attributed to rise in the prevalence of diabetes in Spain. In a society where lifestyle modifications and genetic predisposition collaborate to elevate the prevalence of diabetes, there exists an ongoing surge in the demand for glucose testing solutions that are both efficient and convenient. Furthermore, continuous progress in technological advancements pertaining to glucose testing equipment renders these devices increasingly user-friendly, thereby stimulating the demand. This convergence of medical necessity and technological innovation serves as the driving force behind the expansion of the market.
On the other hand, it is a fact that every market is subject to certain limitations, which are the forces that hinder unrestricted growth. In the context of the Spain point-of-care glucose testing market, pricing pressures constitute a significant constraint. The pursuit of economical alternatives and need for healthcare budget rationalization frequently led to pricing conflicts, which adversely affect the profitability of market participants. In addition, intricacies of regulations are expected to be bewildering, causing delays in the introduction of novel products and technologies, thereby impeding market expansion.
However, intricacies of market dynamics conceal potential opportunities. The steady increase in diabetes prevalence presents a continuously growing market, and enterprises that invest in innovative solutions are poised to reap the greatest rewards. Moreover, advent of non-invasive glucose monitoring techniques holds a significant shift in the market. In addition, advancements in data connectivity, cloud-based solutions, and mobile health applications have the potential to revolutionize the way glucose data is accessed and managed, thereby creating opportunities for tech-savvy market entrants.The Spain point-of-care glucose testing market is segmented into product type, application, and end user. Further, on the basis of product type, the market is segregated into lancing devices & strips and blood-glucose meter. Depending on application, it is bifurcated into type-1 diabetes and type-2 diabetes. According to end user, the Spain point-of-care glucose testing market is classified into hospitals & clinics, home care settings, and others.The Porter's five forces analysis analyzes the competitive scenario of the Spain point-of-care glucose testing market and role of each stakeholder. These forces include the bargaining power of suppliers, bargaining power of buyers, threat of new entrants, threat of substitutes, and competitive rivalry. The competitive rivalry in the market is intense due to rise in demand for glucose monitoring solutions. Market participants consistently compete for market share and strive to differentiate themselves from their competitors through innovative strategies.
The bargaining power of suppliers is affected by several factors, including uniqueness of product they supply. Suppliers of specialized components or proprietary technologies possess significant leverage during negotiation processes. The bargaining power of buyers is significant as the range of options available to them is extensive, and they frequently possess a significant advantage in the process of negotiating prices and terms.The threat of substitute in the Spain point-of-care glucose testing market is minimal. Although novel technologies are emerging, they have not yet supplanted conventional glucose testing methods. The threat of new entrants in the market is moderate. Despite the presence of regulatory obstacles and the requirement for significant R&D investments, pioneering startups is expected to penetrate the market.
A SWOT analysis serves as the guiding tool that navigates through the strengths, weaknesses, opportunities, and threats that are inherent in the Spain point-of-care glucose testing market. The market presents significant strengths, including rise in the incidence of diabetes, technological progress, and expansion of focus on patient-centered care. These elements establish a sturdy basis for market expansion.Weaknesses encompass pricing pressures, regulatory complexities, and imperative for perpetual innovation to maintain competitiveness. These challenges is expected to impede market participants. However, there are numerous opportunities available in the form of non-invasive monitoring techniques, advancements in data connectivity, and expansion of the market into home care settings. Enterprises that effectively leverage these trends have the potential to secure a more promising future. On the other hand, potential risks that need to be considered are regulatory modifications, competitive forces, and constant pricing pressures. It is imperative for market participants to remain flexible to effectively manage these risks.Key players operating in the market includeAbbott, Bayer, Biomark,LifeScan, Menarini Diagnostics, Nova Biomedical, Nova Biomedtec, Roche, Siemens, and Trinity Biotech.
These market players are making substantial investments in R&D activities with the aim of producing products that yield precise outcomes along with offering effortless usability. With the continuous progress of technology, rise in the development of devices that seamlessly integrate with smartphones and wearable technology is expected, thereby seamlessly incorporating glucose monitoring into individuals' everyday routines. Moreover, companies are adopting several pricing strategies to strike a balance between affordability and profitability.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Product Type
- Lancing Devices and Strips
- Blood-Glucose Meter
- Type
- Lifescan OneTouch Ultra and Lifescan OneTouch Verio
- Accu-Chek Aviva Plus and Accuchek
- Freestyle Lite and Freestyle Precission Neo
- Contour Next
- Others
By Application
- Type-1 Diabetes
- Type-2 Diabetes
By End User
- Hospitals and Clinics
- Home Care Settings
- Others
- Key Market Players
- Abbott
- Bayer
- Biomark
- LifeScan
- Menarini Diagnostics
- Nova Biomedical
- Nova Biomedtec
- Roche
- Siemens
- Trinity Biotech
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter's Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market Size and Forecast, By Product Type
4.2. Lancing Devices and Strips
4.3. Blood-Glucose Meter
CHAPTER 5: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Type-1 Diabetes
5.3. Type-2 Diabetes
CHAPTER 6: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market Size and Forecast, By End User
6.2. Hospitals and Clinics
6.3. Home Care Settings
6.4. Others
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Abbott
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Bayer
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Biomark
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. LifeScan
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Menarini Diagnostics
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Nova Biomedical
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Nova Biomedtec
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Roche
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Siemens
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Trinity Biotech
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 04. ABBOTT: KEY EXECUTIVES
TABLE 05. ABBOTT: COMPANY SNAPSHOT
TABLE 06. ABBOTT: OPERATING SEGMENTS
TABLE 07. ABBOTT: PRODUCT PORTFOLIO
TABLE 08. ABBOTT: KEY STRATERGIES
TABLE 09. BAYER: KEY EXECUTIVES
TABLE 10. BAYER: COMPANY SNAPSHOT
TABLE 11. BAYER: OPERATING SEGMENTS
TABLE 12. BAYER: PRODUCT PORTFOLIO
TABLE 13. BAYER: KEY STRATERGIES
TABLE 14. BIOMARK: KEY EXECUTIVES
TABLE 15. BIOMARK: COMPANY SNAPSHOT
TABLE 16. BIOMARK: OPERATING SEGMENTS
TABLE 17. BIOMARK: PRODUCT PORTFOLIO
TABLE 18. BIOMARK: KEY STRATERGIES
TABLE 19. LIFESCAN: KEY EXECUTIVES
TABLE 20. LIFESCAN: COMPANY SNAPSHOT
TABLE 21. LIFESCAN: OPERATING SEGMENTS
TABLE 22. LIFESCAN: PRODUCT PORTFOLIO
TABLE 23. LIFESCAN: KEY STRATERGIES
TABLE 24. MENARINI DIAGNOSTICS: KEY EXECUTIVES
TABLE 25. MENARINI DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 26. MENARINI DIAGNOSTICS: OPERATING SEGMENTS
TABLE 27. MENARINI DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 28. MENARINI DIAGNOSTICS: KEY STRATERGIES
TABLE 29. NOVA BIOMEDICAL: KEY EXECUTIVES
TABLE 30. NOVA BIOMEDICAL: COMPANY SNAPSHOT
TABLE 31. NOVA BIOMEDICAL: OPERATING SEGMENTS
TABLE 32. NOVA BIOMEDICAL: PRODUCT PORTFOLIO
TABLE 33. NOVA BIOMEDICAL: KEY STRATERGIES
TABLE 34. NOVA BIOMEDTEC: KEY EXECUTIVES
TABLE 35. NOVA BIOMEDTEC: COMPANY SNAPSHOT
TABLE 36. NOVA BIOMEDTEC: OPERATING SEGMENTS
TABLE 37. NOVA BIOMEDTEC: PRODUCT PORTFOLIO
TABLE 38. NOVA BIOMEDTEC: KEY STRATERGIES
TABLE 39. ROCHE: KEY EXECUTIVES
TABLE 40. ROCHE: COMPANY SNAPSHOT
TABLE 41. ROCHE: OPERATING SEGMENTS
TABLE 42. ROCHE: PRODUCT PORTFOLIO
TABLE 43. ROCHE: KEY STRATERGIES
TABLE 44. SIEMENS: KEY EXECUTIVES
TABLE 45. SIEMENS: COMPANY SNAPSHOT
TABLE 46. SIEMENS: OPERATING SEGMENTS
TABLE 47. SIEMENS: PRODUCT PORTFOLIO
TABLE 48. SIEMENS: KEY STRATERGIES
TABLE 49. TRINITY BIOTECH: KEY EXECUTIVES
TABLE 50. TRINITY BIOTECH: COMPANY SNAPSHOT
TABLE 51. TRINITY BIOTECH: OPERATING SEGMENTS
TABLE 52. TRINITY BIOTECH: PRODUCT PORTFOLIO
TABLE 53. TRINITY BIOTECH: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 10. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)
FIGURE 11. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. ABBOTT: NET SALES, 2020-2022*($MILLION)
FIGURE 21. ABBOTT: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. BAYER: NET SALES, 2020-2022*($MILLION)
FIGURE 24. BAYER: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. BAYER: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. BIOMARK: NET SALES, 2020-2022*($MILLION)
FIGURE 27. BIOMARK: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. BIOMARK: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. LIFESCAN: NET SALES, 2020-2022*($MILLION)
FIGURE 30. LIFESCAN: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. LIFESCAN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. MENARINI DIAGNOSTICS: NET SALES, 2020-2022*($MILLION)
FIGURE 33. MENARINI DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. MENARINI DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. NOVA BIOMEDICAL: NET SALES, 2020-2022*($MILLION)
FIGURE 36. NOVA BIOMEDICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. NOVA BIOMEDICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. NOVA BIOMEDTEC: NET SALES, 2020-2022*($MILLION)
FIGURE 39. NOVA BIOMEDTEC: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. NOVA BIOMEDTEC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. ROCHE: NET SALES, 2020-2022*($MILLION)
FIGURE 42. ROCHE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. ROCHE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. SIEMENS: NET SALES, 2020-2022*($MILLION)
FIGURE 45. SIEMENS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. SIEMENS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. TRINITY BIOTECH: NET SALES, 2020-2022*($MILLION)
FIGURE 48. TRINITY BIOTECH: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. TRINITY BIOTECH: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security